Taranabant (MK-0364)
Taranabant, aslo known as MK-0364, a cannabinoid receptor type 1 inverse agonist being investigated as a potential treatment for obesity due to its anorectic effects. Taranabant reduces abdominal pain and increases intestinal transit in mice. It was discovered by Merck & Co. In October 2008, Merck has stopped its phase III clinical trials with the drugs due to high level of central side effects, mainly depression and anxiety.
Supplier | Ace Therapeutics |
---|---|
Product # | SMD029 |
CAS # | 701977-09-5 |
Pricing | Customizable size, Inquiry |
Synonym | MK-0364, MK 0364, MK0364, Taranabant |
Product Category | Lab-use Small Molecule Drugs |
Chemical Formula | C27H25ClF3N3O2 |
Exact Mass | 515.1587 |
Molecular Weight | 515.96 |
Elemental Analysis | C, 62.85; H, 4.88; Cl, 6.87; F, 11.05; N, 8.14; O, 6.20 |
IUPAC/Chemical Name | N-((2S,3S)-4-(4-chlorophenyl)-3-(3-cyanophenyl)butan-2-yl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide |
InChi Key | QLYKJCMUNUWAGO-GAJHUEQPSA-N |
InChi Code | InChI=1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1 |
SMILES Code | CC(OC1=NC=C(C(F)(F)F)C=C1)(C)C(N[C@H]([C@H](C2=CC=CC(C#N)=C2)CC3=CC=C(Cl)C=C3)C)=O |
Appearance | Solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
Solubility | Soluble in DMSO, not in water |
Shelf Life | >2 years if stored properly |
Drug Formulation | This drug may be formulated in DMSO |
Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
HS Tariff Code | 2934.99.9001 |
Class-2 | Anxiety |